News

India Enforces Stricter Drug Manufacturing Standards After Fatal Cough Syrup Tragedy

The Indian government has taken a firm stance on pharmaceutical quality control, rejecting requests from drug manufacturers for another extension to upgrade their facilities to meet international safety standards.

• By Newsdesk
• New Delhi
• Oct 18, 2025

News

The Indian government has taken a firm stance on pharmaceutical quality control, rejecting requests from drug manufacturers for another extension to upgrade their facilities to meet international safety standards. The move follows a series of cough syrup-related deaths that exposed critical lapses in drug manufacturing practices and triggered widespread concern over the country’s pharmaceutical oversight.

A pivotal deadline

In late 2023, the Central Drugs Standard Control Organisation (CDSCO) ordered all pharmaceutical companies to upgrade their plants in line with World Health Organization (WHO) Good Manufacturing Practices. The directive focused on preventing cross-contamination, improving hygiene, and ensuring stricter testing of finished drug batches.

Large manufacturers were expected to comply by June 2024, while smaller firms were given until December 2024. However, the government has now refused any further deadline extensions, citing the urgent need to prevent further tragedies and restore public trust.

Triggered by tragedy

The stricter stance was prompted by the deaths of at least 24 children in Madhya Pradesh earlier this year after consuming a locally manufactured cough syrup branded Coldrif. Tests revealed the syrup contained dangerously high levels of diethylene glycol (DEG) — a toxic chemical often used in industrial solvents — at nearly 500 times the permissible limit.

The incident renewed scrutiny on India’s reputation as the “pharmacy of the world,” highlighting how substandard production practices in smaller facilities can have devastating consequences both domestically and internationally.

Regulators say “no more extensions”

Industry associations had appealed for more time, arguing that compliance costs could overwhelm small and medium-sized enterprises. However, regulators dismissed the request, stating that safety could not be compromised for commercial convenience.

“The deadline cannot be extended again and again — people are dying,” said a senior government official, underscoring the urgency of enforcing manufacturing reforms. Officials noted that the dilapidated condition of the plant responsible for the Coldrif syrup deaths demonstrated why such reforms were non-negotiable.

Impact on industry and exports

India’s pharmaceutical sector, valued at around US $50 billion and home to more than 3,000 companies operating over 10,000 facilities, now faces a crucial inflection point. While large firms are expected to meet compliance requirements smoothly, smaller manufacturers are struggling to afford the costly upgrades.

To balance reform with export efficiency, the government is also phasing out an older requirement that mandated cough syrup batches to undergo additional testing at government laboratories before export. The focus will now shift to ensuring that every manufacturing unit adheres to WHO-approved standards from the ground up.

What it means for patients and producers

For consumers, the government’s move represents a long-awaited commitment to safer medicines and stronger regulatory enforcement. For manufacturers, it signals a tough new reality: those unable to meet compliance standards risk losing licenses or market access.

While some smaller companies warn that these measures could cause supply shortages and job losses, regulators maintain that temporary disruption is preferable to risking more lives.

Looking ahead

The next few months will be a litmus test for India’s pharmaceutical industry as it races to align with global safety norms. Officials have reiterated that the responsibility for product quality lies squarely with manufacturers, not the government.

India’s tougher stance marks a turning point for the nation’s drug industry — one that prioritizes patient safety and global credibility over speed and scale. The era of lax compliance appears to be ending, ushering in a new chapter of accountability for the world’s largest supplier of generic medicines.